|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2002-6-21
|
|
pubmed:abstractText |
Cystemustine is a chloroethylnitrosourea mostly active in humans against glioma and melanoma. The present report describes the results of a new phase I trial with cystemustine administered on a weekly schedule. The pharmacokinetic and pharmacodynamic properties of cystemustine were investigated.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
760-9
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12075746-Adolescent,
pubmed-meshheading:12075746-Adult,
pubmed-meshheading:12075746-Aged,
pubmed-meshheading:12075746-Dose-Response Relationship, Drug,
pubmed-meshheading:12075746-Drug Administration Schedule,
pubmed-meshheading:12075746-Female,
pubmed-meshheading:12075746-Follow-Up Studies,
pubmed-meshheading:12075746-Humans,
pubmed-meshheading:12075746-Linear Models,
pubmed-meshheading:12075746-Male,
pubmed-meshheading:12075746-Maximum Tolerated Dose,
pubmed-meshheading:12075746-Middle Aged,
pubmed-meshheading:12075746-Neoplasms,
pubmed-meshheading:12075746-Nitrosourea Compounds,
pubmed-meshheading:12075746-Probability,
pubmed-meshheading:12075746-Survival Analysis,
pubmed-meshheading:12075746-Treatment Outcome
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Pharmacokinetic study of cystemustine, administered on a weekly schedule in cancer patients.
|
|
pubmed:affiliation |
Unité d'Oncothérapie Appliquée, Centre Jean Perrin, Clermont-Ferrand, France. recherche.clinique@cjp.u-clermont1.fr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
